StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Aggregate of 7 sell-side ratings as of 2026-05-01. Stonvex does not endorse these ratings.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Next report date, year-over-year trend, and recent quarter history.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $1.35 | $1.31 | -2.96% | 0.1M |
| 05-18 | $1.31 | $1.36 | +3.82% | 0.1M |
| 05-19 | $1.36 | $1.31 | -3.68% | 0.0M |
| 05-20 | $1.31 | $1.35 | +3.05% | 0.0M |
| 05-21 | $1.35 | $1.42 | +5.19% | 0.0M |
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows BIVI's percentile within the scored universe — observational ranking, not a recommendation.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-08-13 | Q3 2016 2016-09-30 | Q3 2015 2015-09-30 |
|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 |
Operating Income | Not available | $-351.35K | $-54.63K |
Net Income | Not available | $-351.34K | $-54.57K |
EPS (Diluted) | $-0.53 | Not available | Not available |
Total Assets | Not available | $2.54M | $266.02K |
Total Liabilities | Not available | Not available | Not available |
Cash & Equivalents | Not available | $8.74K | $265.52K |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available |
Shares Outstanding | Not available | 87.21M | 87.21M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.